Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis.

Andorrà M, Alba-Arbalat S, Camos-Carreras A, Gabilondo I, Fraga-Pumar E, Torres-Torres R, Pulido-Valdeolivas I, Tercero-Uribe AI, Guerrero-Zamora AM, Ortiz-Perez S, Zubizarreta I, Sola-Valls N, Llufriu S, Sepulveda M, Martinez-Hernandez E, Armangue T, Blanco Y, Villoslada P, Sanchez-Dalmau B, Saiz A, Martinez-Lapiscina EH.

JAMA Neurol. 2019 Sep 30. doi: 10.1001/jamaneurol.2019.3283. [Epub ahead of print]

PMID:
31566686
2.

Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab.

Leszczynska A, Molins B, Fernández E, Adán A, Ortiz-Perez S.

Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2307-2314. doi: 10.1007/s00417-019-04419-7. Epub 2019 Jul 23.

PMID:
31338585
3.

Sebaceous carcinoma of the caruncle.

Salazar-Villegas Á, Matas J, Palma-Carvajal F, González-Valdivia H, Alos L, Ortiz-Pérez S.

J Fr Ophtalmol. 2019 Oct;42(8):925-927. doi: 10.1016/j.jfo.2019.04.014. Epub 2019 Jun 6. No abstract available.

PMID:
31178073
4.

Early retinal atrophy predicts long-term visual impairment after acute optic neuritis.

Sanchez-Dalmau B, Martinez-Lapiscina EH, Torres-Torres R, Ortiz-Perez S, Zubizarreta I, Pulido-Valdeolivas IV, Alba-Arbalat S, Guerrero-Zamora A, Calbet D, Villoslada P.

Mult Scler. 2018 Aug;24(9):1196-1204. doi: 10.1177/1352458517718628. Epub 2017 Jul 3.

PMID:
28669275
5.

[What would you do in front of a patient with a Horner syndrome?]

Camós-Carreras A, Fontana S, Ortiz-Pérez S.

Semergen. 2018 Mar;44(2):131-134. doi: 10.1016/j.semerg.2016.08.004. Epub 2016 Oct 20. Spanish.

PMID:
27773627
6.

Use of Alleviating Maneuvers for Periocular Facial Dystonias.

Kilduff CL, Casswell EJ, Salam T, Hersh D, Ortiz-Perez S, Ezra D.

JAMA Ophthalmol. 2016 Nov 1;134(11):1247-1252. doi: 10.1001/jamaophthalmol.2016.3277.

PMID:
27606483
7.

Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders.

Martinez-Lapiscina EH, Sepulveda M, Torres-Torres R, Alba-Arbalat S, Llufriu S, Blanco Y, Guerrero-Zamora AM, Sola-Valls N, Ortiz-Perez S, Villoslada P, Sanchez-Dalmau B, Saiz A.

Ther Adv Neurol Disord. 2016 Sep;9(5):436-40. doi: 10.1177/1756285616655264. Epub 2016 Aug 15. No abstract available.

8.

Visual field impairment captures disease burden in multiple sclerosis.

Ortiz-Perez S, Andorra M, Sanchez-Dalmau B, Torres-Torres R, Calbet D, Lampert EJ, Alba-Arbalat S, Guerrero-Zamora AM, Zubizarreta I, Sola-Valls N, Llufriu S, Sepúlveda M, Saiz A, Villoslada P, Martinez-Lapiscina EH.

J Neurol. 2016 Apr;263(4):695-702. doi: 10.1007/s00415-016-8034-2. Epub 2016 Feb 9.

PMID:
26860093
9.

Color vision impairment in multiple sclerosis points to retinal ganglion cell damage.

Lampert EJ, Andorra M, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Sepúlveda M, Sola N, Saiz A, Sánchez-Dalmau B, Villoslada P, Martínez-Lapiscina EH.

J Neurol. 2015 Nov;262(11):2491-7. doi: 10.1007/s00415-015-7876-3. Epub 2015 Aug 11.

PMID:
26259563
10.

Dynamics of retinal injury after acute optic neuritis.

Gabilondo I, Martínez-Lapiscina EH, Fraga-Pumar E, Ortiz-Perez S, Torres-Torres R, Andorra M, Llufriu S, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

Ann Neurol. 2015 Mar;77(3):517-28. doi: 10.1002/ana.24351. Epub 2015 Feb 14.

PMID:
25559267
11.

The multiple sclerosis visual pathway cohort: understanding neurodegeneration in MS.

Martínez-Lapiscina EH, Fraga-Pumar E, Gabilondo I, Martínez-Heras E, Torres-Torres R, Ortiz-Pérez S, Llufriu S, Tercero A, Andorra M, Roca MF, Lampert E, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P.

BMC Res Notes. 2014 Dec 15;7:910. doi: 10.1186/1756-0500-7-910.

12.

The visual pathway as a model to understand brain damage in multiple sclerosis.

Martínez-Lapiscina EH, Sanchez-Dalmau B, Fraga-Pumar E, Ortiz-Perez S, Tercero-Uribe AI, Torres-Torres R, Villoslada P.

Mult Scler. 2014 Nov;20(13):1678-85. doi: 10.1177/1352458514542862. Epub 2014 Jul 10. Review.

PMID:
25013155
13.

Colour vision impairment is associated with disease severity in multiple sclerosis.

Martínez-Lapiscina EH, Ortiz-Pérez S, Fraga-Pumar E, Martínez-Heras E, Gabilondo I, Llufriu S, Bullich S, Figueras M, Saiz A, Sánchez-Dalmau B, Villoslada P.

Mult Scler. 2014 Aug;20(9):1207-16. doi: 10.1177/1352458513517591. Epub 2014 Jan 7.

PMID:
24399824
14.

Retinal periphlebitis is associated with multiple sclerosis severity.

Ortiz-Pérez S, Martínez-Lapiscina EH, Gabilondo I, Fraga-Pumar E, Martínez-Heras E, Saiz A, Sanchez-Dalmau B, Villoslada P.

Neurology. 2013 Sep 3;81(10):877-81. doi: 10.1212/WNL.0b013e3182a3525e. Epub 2013 Jul 31.

15.

Clinical anatomy of the periocular region.

Shams PN, Ortiz-Pérez S, Joshi N.

Facial Plast Surg. 2013 Aug;29(4):255-63. doi: 10.1055/s-0033-1349365. Epub 2013 Jul 24.

PMID:
23884846
16.

Retrograde retinal damage after acute optic tract lesion in MS.

Gabilondo I, Sepúlveda M, Ortiz-Perez S, Fraga-Pumar E, Martínez-Lapiscina EH, Llufriu S, Solá N, Saiz A, Sanchez-Dalmau B, Villoslada P.

J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):824-6. doi: 10.1136/jnnp-2012-304854. Epub 2013 May 28. No abstract available.

PMID:
23715916
17.

[Is preseptal cellulitis of the eyelid always a trivial disease?].

Ortiz-Pérez S, Latasiewicz M, Castellá C, Fernández E.

Enferm Infecc Microbiol Clin. 2012 Aug;30(7):422-3. doi: 10.1016/j.eimc.2012.01.027. Epub 2012 Mar 8. Spanish. No abstract available.

PMID:
22405141
18.

Neuro-ophthalmological features of primary diffuse leptomeningeal gliomatosis.

Noval S, Ortiz-Pérez S, Sánchez-Dalmau BF, Ruiz-Ares G, Arpa J, Adán A.

J Neuroophthalmol. 2011 Dec;31(4):299-305. doi: 10.1097/WNO.0b013e31821ee5c2.

PMID:
21623228
19.

Two cases of drug-induced orbital inflammatory disease.

Ortiz-Perez S, Fernandez E, Molina JJ, Sanchez-Dalmau B, Navarro M, Corretger X, Olver JM.

Orbit. 2011 Jan;30(1):37-9. doi: 10.3109/01676830.2010.535641.

PMID:
21281079
20.

Oxaliplatin-Related Ocular Toxicity.

Mesquida M, Sanchez-Dalmau B, Ortiz-Perez S, Pelegrín L, Molina-Fernandez JJ, Figueras-Roca M, Casaroli-Marano R, Adán A.

Case Rep Oncol. 2010 Nov 22;3(3):423-427.

Supplemental Content

Loading ...
Support Center